Pacific Edge Limited (PFGTF) has released an update.
Pacific Edge Limited, a New Zealand-based global cancer diagnostics firm, has clarified that its recent promotional activities for the Cxbladder tests at the AUA Annual Meeting are not material information, correcting a previous misstatement. The company emphasizes the non-material nature of the event as it had already disclosed the key details in an earlier investor update. Pacific Edge continues to advance in bladder cancer diagnostics, with its Cxbladder test gaining traction among U.S. urologists and available to a significant portion of New Zealand’s population.
For further insights into PFGTF stock, check out TipRanks’ Stock Analysis page.
